---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-23-000012"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:25:39.445404+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amneal reports preliminary Q1 2023 revenue $550-560M (+12% YoY); affirms FY guidance

## Summary
- Net revenue $550-560M, up ~12% YoY; loss before taxes $10M-$0 (improvement ~50%).
- Adjusted EBITDA $115-120M, up ~18% YoY.
- Long-term debt $2.692B; net debt reduced to $2.541B from $2.647B at Dec 31.
- Management cites strong generics, biosimilars uptake, Rytary/Unithroid growth; IPX203 PDUFA June 30.
- Full year 2023 financial guidance affirmed.

## SEC filing metadata
- accession: 0001723128-23-000012
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000012/0001723128-23-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000012/amrx-20230417.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-23-000012
- JSON: https://secwatch.observer/filing/0001723128-23-000012.json
- Plain text: https://secwatch.observer/filing/0001723128-23-000012.txt

## Key facts
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: revenue $550 million to $560 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $550 million to $560 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: 2023. Unaudited Preliminary Financial Results for the First Quarter Ended March 31, 2023 Based on preliminary financial information, Amneal expects to report: • Net revenue of $550 million to $560 million, an increase of approximately 12% compared to the first quarter of 2022 • Loss before income taxes of $10 million to $0, an improvement of approximately 50%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000012/0001723128-23-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.